| Bioactivity | Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases[1]. | ||||||||||||
| Invitro | Soraprazan (BYK61359) is a potent inhibitor of gastric H,K-ATPase, with an IC50 of 0.1 μM when measured in ion-leaky vesicles in the presence of 1 mM potassium. Soraprazan (BYK61359) also effectively inhibits dibutyryl cAMP-stimulated [14C]AP accumulation in isolated gastric glands with an IC50 of 0.19 μM (0.09-0.40 μM geometric mean from n=6 with 95% confidence limits)[1]. | ||||||||||||
| In Vivo | Soraprazan (1-27 μmol/kg; p.o.) shows rapid and consistent inhibition of acid secretion in dog [1]. | ||||||||||||
| Name | Soraprazan | ||||||||||||
| CAS | 261944-46-1 | ||||||||||||
| Formula | C21H25N3O3 | ||||||||||||
| Molar Mass | 367.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Simon WA, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. |
Soraprazan
CAS: 261944-46-1 F: C21H25N3O3 W: 367.44
Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.